Finance

Beta
Lister
Aksjesektorer
Symboler
Symboler
Pris
Endring
Endring (%)
Trend
Forrige pris ved stengetid
ƅpne
HĆøy
Lav
Volum
Markedsverdi
SIXB
Materials
SIXB
Materials
SIXB
āˆ’0,21%
1Ā 091,51
āˆ’2,30
āˆ’0,21%
ā€”1Ā 093,811Ā 096,521Ā 100,221Ā 091,51ā€”ā€”
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
ā€”608,77608,77612,97608,77ā€”ā€”
SIXE
Energy
SIXE
Energy
SIXE
āˆ’1,34%
1Ā 237,98
āˆ’16,83
āˆ’1,34%
ā€”1Ā 254,811Ā 253,011Ā 253,871Ā 226,33ā€”ā€”
SIXI
Industrials
SIXI
Industrials
SIXI
āˆ’0,93%
1Ā 744,71
āˆ’16,40
āˆ’0,93%
ā€”1Ā 761,111Ā 764,271Ā 766,881Ā 744,71ā€”ā€”
SIXM
Financials
SIXM
Financials
SIXM
āˆ’0,37%
640,18
āˆ’2,40
āˆ’0,37%
ā€”642,58644,87648,48640,18ā€”ā€”
SIXR
Staples
SIXR
Staples
SIXR
āˆ’0,18%
849,58
āˆ’1,55
āˆ’0,18%
ā€”851,13855,66858,75845,56ā€”ā€”
SIXRE
Real estate
SIXRE
Real estate
SIXRE
āˆ’0,23%
217,48
āˆ’0,50
āˆ’0,23%
ā€”217,98217,98218,65216,88ā€”ā€”
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3Ā 260,69
+48,86
+1,52%
ā€”3Ā 211,833Ā 227,213Ā 268,383Ā 226,55ā€”ā€”
SIXU
Utilities
SIXU
Utilities
SIXU
āˆ’0,69%
942,45
āˆ’6,53
āˆ’0,69%
ā€”948,98948,58957,83941,97ā€”ā€”
SIXV
Health care
SIXV
Health care
SIXV
āˆ’0,52%
1Ā 466,80
āˆ’7,72
āˆ’0,52%
ā€”1Ā 474,521Ā 479,031Ā 481,041Ā 466,80ā€”ā€”
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2Ā 397,50
+5,38
+0,22%
ā€”2Ā 392,122Ā 396,952Ā 421,222Ā 382,32ā€”ā€”
ATAI:NASDAQ
AtaiBeckley Inc
4,14Ā USD
āˆ’0,60%
(āˆ’0,025) 1Ā D
4,18Ā USD
+1,09% (+0,045)
FĆør bĆørsĆ„pning
Stengt: 1. mai, 16:00:04 GMT-4  ·   USD
Alle symboler
SymbolPrisEndringEndring (%)
Genererer viktig statistikk for ATAIĀ ā€¦
ƅpne
4,15Ā USD
HĆøy
4,20Ā USD
Lav
4,08Ā USD
Markedsverdi
1,52Ā mrd.
Volum
5,52k
52Ā u hĆøy
6,75Ā USD
52Ā u lav
1,29Ā USD
EPS
āˆ’2,91Ā USD
Beta
1,59
UtestƄende aksjer
366,92Ā mill.
Antall ansatte
99
Nyhetssaker
Fra kilder pƄ nettet
Profil
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Om AtaiBeckley Inc
Administrerende direktĆørFlorian Brand
Ansatte99
Grunnlagt2018
Hovedkontor-
Sektor-
Nettstedataibeckley.com
Tidligere rapporterAlle verdier i USD
Loading Previous Earnings...
Resultatregnskap
Inntekt
Nettoinntekt
Alle verdier i USD
mars 2025
juni 2025
sep. 2025
des. 2025
Inntekt
1,56Ā mill.
719,00k
749,00k
1,07Ā mill.
Varekostnad
10,84Ā mill.
10,51Ā mill.
14,68Ā mill.
10,91Ā mill.
Direkte driftskostnader
10,84Ā mill.
10,51Ā mill.
14,68Ā mill.
10,91Ā mill.
Utgifter til forskning og utvikling
-
582,00k
-
4,00Ā mill.
Totale kostnader til forskning og utvikling
-
-
-
-
Salgskostnader, generelle kostnader og administrative kostnader
9,99Ā mill.
14,90Ā mill.
14,50Ā mill.
24,40Ā mill.
Driftskostnader
9,99Ā mill.
15,48Ā mill.
14,50Ā mill.
28,41Ā mill.
Totale driftskostnader
20,82Ā mill.
25,99Ā mill.
29,18Ā mill.
39,32Ā mill.
Driftsinntekter
āˆ’19,27Ā mill.
āˆ’25,27Ā mill.
āˆ’28,44Ā mill.
āˆ’38,25Ā mill.
Andre ikke-operasjonelle inntekter
āˆ’13,01Ā mill.
āˆ’6,33Ā mill.
āˆ’51,25Ā mill.
13,99Ā mill.
EBT inkludert uvanlige elementer
āˆ’26,34Ā mill.
āˆ’27,68Ā mill.
āˆ’61,00Ā mill.
āˆ’544,84Ā mill.
EBT uten uvanlige elementer
āˆ’32,54Ā mill.
āˆ’30,16Ā mill.
āˆ’79,20Ā mill.
āˆ’23,71Ā mill.
Kostnad for inntektsskatt
128,00k
65,00k
102,00k
3,00k
Faktisk avgiftssats
āˆ’0,49Ā %
āˆ’0,23Ā %
āˆ’0,17Ā %
-
Andre driftskostnader
-
-
-
-
Nettoinntekt
āˆ’26,43Ā mill.
āˆ’27,73Ā mill.
āˆ’61,07Ā mill.
āˆ’544,81Ā mill.
Netto fortjenestemargin
āˆ’1Ā 699,74Ā %
āˆ’3Ā 856,61Ā %
āˆ’8Ā 154,07Ā %
āˆ’51Ā 108,16Ā %
Resultat per aksje
āˆ’0,15
āˆ’0,14
āˆ’0,28
āˆ’1,73
Rente- og investeringsinntekter
186,00k
248,00k
504,00k
542,00k
Rentekostnader
āˆ’900,00k
āˆ’264,00k
-
-
Netto rentekostnader
āˆ’714,00k
āˆ’16,00k
504,00k
542,00k
Avskrivnings- og amortiseringskostnader
-
-
-
-
EBITDA
āˆ’19,05Ā mill.
āˆ’25,05Ā mill.
āˆ’28,20Ā mill.
āˆ’37,91Ā mill.
Gevinst eller tap ved salg av eiendeler
-
-
-
692,00k
AI-innhold kan inneholde feil. Finn ut mer
HjelpSend tilbakemeldingPersonvernVilkƄrAnsvarsfraskrivelse

Utforskning

Mine oppgaver
Du har ikke opprettet noen oppgaver ennƄ
Oppgavene dine vises her. Planlegg oppgaver og la Google Finance jobbe for deg mens du er borte.
Maler
Sammendrag om overvƄkningsliste
En daglig analyse av overvĆ„kningslisten din fĆør markedet Ć„pner
Kommende inntektsrapport
Kommende inntektsrapporter i lĆøpet av uken
Unormal volatilitet og unormalt volum
Tidlig varsel om volatilitet og volum i dag
AI-innhold kan inneholde feil. Finn ut mer
HjelpSend tilbakemeldingPersonvernVilkƄrAnsvarsfraskrivelse